Skip to content

Study · Randomized controlled trial · 2025

8 results

Subgroup analysis by sex and baseline BMI in people with a BMI ≥27 kg/m2 in the phase 2 trial of survodutide, a glucagon/GLP-1 receptor dual agonist.

le Roux CW, Steen O, Lucas KJ, Startseva E, Unseld A, Hussain SA, Hennige AM

Diabetes, obesity & metabolism16 Jan 2025Cited by 10 (Europe PMC)

PMID39821928 (opens in a new tab)PMCIDPMC11885088 (opens in a new tab)DOI10.1111/dom.16167 (opens in a new tab)PepBankPUB-39821928
Read at sourcePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In people with a BMI of 27 kg/m2 or more, survodutide was associated with clinically meaningful bodyweight reductions compared with placebo in prespecified sex and baseline BMI subgroups.

    In plain wordsIn people with excess weight, survodutide was linked to meaningful weight loss compared with placebo in men, women and BMI subgroups.

    Peptide
    Survodutide
    Outcome
    DecreaseBodyweight reduction versus placebo in sex and BMI subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  2. 02HumanRandomized controlled trialEfficacy outcome

    In people with a BMI of 27 kg/m2 or more, survodutide was associated with clinically meaningful waist circumference reductions compared with placebo in prespecified sex and baseline BMI subgroups.

    In plain wordsIn people with excess weight, survodutide was linked to meaningful waist size reduction compared with placebo in men, women and BMI subgroups.

    Peptide
    Survodutide
    Outcome
    DecreaseWaist circumference reduction versus placebo in sex and BMI subgroups
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    survodutide was associated with clinically meaningful reductions in bodyweight and waist circumference when compared with placebo, in prespecified subgroups based on sex and baseline BMI
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  3. 03HumanRandomized controlled trialSafety outcome

    Rates of adverse events with survodutide were comparable between subgroups defined by sex and baseline BMI.

    In plain wordsSide effects on survodutide occurred at similar rates in men, women and BMI subgroups.

    Peptide
    Survodutide
    Outcome
    No significant changeAdverse event rates by sex and baseline BMI
    Study

    n: not reported in source

    Comparator
    Other subgroups
    Outcome group
    Adverse events · Whole body
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Rates of adverse events (AEs) were comparable between subgroups for sex and baseline BMI.
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  4. 04HumanRandomized controlled trialSafety outcome

    Nausea was the most frequently reported gastrointestinal adverse event of survodutide in all sex and BMI subgroups.

    In plain wordsNausea was the most common stomach or bowel side effect of survodutide in all subgroups.

    Peptide
    Survodutide
    Outcome
    Not applicableNausea as most frequent gastrointestinal adverse event
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Nausea was the most frequently reported gastrointestinal AE in all subgroups.
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  5. 05HumanObservational studyEfficacy outcome

    In people with a BMI of 27 kg/m2 or more, females had greater bodyweight reductions than males after 46 weeks of survodutide.

    In plain wordsIn people with excess weight on survodutide, women lost more body weight than men after 46 weeks.

    Peptide
    Survodutide
    Outcome
    DecreaseBodyweight reduction by sex
    Study

    n: not reported in source

    Comparator
    Males
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    After 46 weeks of survodutide treatment, females had greater reductions in bodyweight and waist circumference than males.
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  6. 06HumanObservational studyEfficacy outcome

    In people with a BMI of 27 kg/m2 or more, females had greater waist circumference reductions than males after 46 weeks of survodutide.

    In plain wordsIn people with excess weight on survodutide, women lost more waist size than men after 46 weeks.

    Peptide
    Survodutide
    Outcome
    DecreaseWaist circumference reduction by sex
    Study

    n: not reported in source

    Comparator
    Males
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    After 46 weeks of survodutide treatment, females had greater reductions in bodyweight and waist circumference than males.
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  7. 07HumanObservational studyEfficacy outcome

    Participants with a lower baseline BMI had greater proportional bodyweight reductions with survodutide than those with a higher baseline BMI.

    In plain wordsOn survodutide, people with a lower starting BMI lost a larger share of their body weight than people with a higher starting BMI.

    Peptide
    Survodutide
    Outcome
    DecreaseProportional bodyweight reduction by baseline BMI
    Study

    n: not reported in source

    Comparator
    Higher baseline BMI
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants with a lower baseline BMI had greater proportional reductions in bodyweight than those with a higher baseline BMI; the trend was reversed for reductions in waist circumference.
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).
  8. 08HumanObservational studyEfficacy outcome

    For waist circumference, the BMI trend was reversed: reductions with survodutide were greater with a higher baseline BMI.

    In plain wordsOn survodutide, waist size fell more in people with a higher starting BMI than in people with a lower starting BMI.

    Peptide
    Survodutide
    Outcome
    DecreaseWaist circumference reduction by baseline BMI
    Study

    n: not reported in source

    Comparator
    Lower baseline BMI
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    0.6, 2.4, 3.6 or 4.8 mg once weekly · subcutaneous · 46 weeksAs given in this study (human).

    Source sentences

    Summary
    Participants with a lower baseline BMI had greater proportional reductions in bodyweight than those with a higher baseline BMI; the trend was reversed for reductions in waist circumference.
    1 context sentence
    Summary · context
    Totally 387 people (aged 18-75 years, BMI ≥27 kg/m2, without diabetes) were randomized 1:1:1:1:1 to once-weekly subcutaneous survodutide (0.6, 2.4, 3.6 or 4.8 mg) or placebo for 46 weeks (20-week dose escalation; 26-week dose maintenance).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04667377

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Boehringer Ingelheimn = 3878 Mar 2021 to 7 Oct 2022

Obesity

Trial pageClinicalTrials.govUpdated 2 Nov 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.